Previous 10 | Next 10 |
2023-11-09 07:50:27 ET More on Repare Therapeutics Repare: Potential Of Camonsertib With Several Shots On Goal Repare Therapeutics: A Compelling Bet On Synthetic Lethality Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for...
Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors Repare to host conference call and webcas...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Repare Therapeutics Inc. (RPTX) is expected to report $-0.86 for Q3 2023
Event to be webcast live on Wednesday, November 15 at 8:00 a.m. ET Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to pre...
2023-11-06 19:43:49 ET Summary Repare Therapeutics presented preliminary results from the phase 1 MYTHIC study using the lunresertib and camonsertib combination for the treatment of patients with multiple solid tumor types. The biotech plans to complete the phase 1 expansion porti...
2023-11-06 12:35:26 ET Moe on Repare Therapeutics Repare Therapeutics: A Compelling Bet On Synthetic Lethality Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare Therape...
2023-11-06 10:01:49 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...
Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and 50% RECIST response in patients with heavily pre-treated gynecologic tumors, including endome...
2023-10-03 09:00:00 ET Summary Repare Therapeutics shows clinical and financial strength, with diverse cancer therapies and a robust balance sheet. Despite promising Q2 results, elevated put activity and 7.32% short interest warrant investor caution. "Buy" recommendation based...
News, Short Squeeze, Breakout and More Instantly...
Repare Therapeutics Inc. Company Name:
RPTX Stock Symbol:
NASDAQ Market:
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced s...
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial resu...
Shares of RingCentral, Inc. (NYSE:RNG) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarte...